- 3 hrs ago Dustin Hoffman Birthday Special Irresistibly Versatile Actor Turns 85
- 11 hrs ago It’s Raining Offers On Amazon: Bag 60% Off On Handbags Today!
- 15 hrs ago Best And Perfect Travel Companions Based On The Zodiac Signs
- 15 hrs ago National Handloom Day: Tiger Stripes Collection Chakradhara By Warp N Weft And WWF India
- Sports CWG 2022: Left young by his mother, Eldhose Paul struggled for pocket money in his college days
- Movies Khatron Ke Khiladi 12 August 7 Highlights: Chetna Pande Gets Eliminated From The Show
- News BJP-JDU rift widens? Bihar CM Kumar calls meeting of party MLAs, MPs
- Education How Can MSc Business Analytics Boost Your Career Growth?
- Automobiles Royal Enfield Hunter 350 Launched At Rs 1,49,900 - The Lightest Enfield
- Travel Phang Nga Bay: James Bond Island
- Finance 'Cipla' Betting Big on Digitisation And Emerging Segments
- Technology Jio Games Watch Will Let You Earn Money While Gaming
Government advisory panel NTAGI will meet on Thursday to review data on Covaxin and Corbevax vaccines for the 6-12 age group and also deliberate on reducing the gap between the second and precaution doses from the current nine to six months.
The National Technical Advisory Group on Immunisation (NTAGI) will hold its meeting amid a fresh spike in COVID-19 cases in the country. Those aged 12 years and above are vaccinated against COVID-19.
The agenda for the NTAGI's Standing Technical Sub-Committee (STSC) meeting includes discussion on a study by the CMC Vellore on the feasibility of allowing a precaution dose of a COVID-19 vaccine separate from the one used for primary vaccination, the Covid burden in paediatric population, and the long-term safety of the ZyCoV-D vaccine, official sources said.
India's drug regulator in April granted emergency use authorisation for Biological E's COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech's Covaxin for children in the age group of six to 12 years.
The Covid Working Group of NTAGI, which reviewed the findings of the Christian Medical College (CMC) Vellore study in May found a lack of uniformity in results upon the mixing of jabs for booster shots.
The study stated that the scientific evidence showed that administering a booster dose of Covishield after primary vaccination with Covaxin gives 6 to 10 times higher antibody level as compared to when Covaxin is given as a precaution dose after a gap of six months after the primary schedule.
"However, the same advantage was not observed when Covaxin as a booster shot was given after two Covishield doses," an official source had told PTI.
Considering programmatic challenges, it was decided that the matter would be discussed in the NTAGI's STSC meeting for a final recommendation.
Also, the committee in its meeting held in May cited a lack of clear evidence of the benefit of reducing the interval between the last dose of the primary schedule and the protection dose. It felt that studies presented for the session had valuable scientific information but were not helpful in taking a decision on a current policy question.
The ICMR was then asked to extract data from the National Vaccine Tracker Platform to determine the breakthrough infection rates at three, six and nine months after completion of the primary schedule before the onset of the Omicron wave and overlapping with the Omicron wave.
It was informed that there is no data available on the comparative effectiveness of booster/protection doses administered at six months versus nine months.
Currently, all those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.
The Union government last month allowed citizens and students travelling overseas to get the shot before the stipulated nine-month waiting period as required by the guidelines of the destination country.
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- wellnessBiological E Ltd Reduces Price Of Its Covid-19 Vaccine Corbevax To Rs 250 Per Dose
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- kidsCOVID-19 Vaccine: Government Panel Recommends EUA For Corbevax For Kids Between 5-11 Years Age Groups
- wellnessCOVID-19: DGCI Grants Restricted Emergency-Use Nod To Corbevax Vaccine For 12-18 Age Group
- wellnessCorbevax: What Do We Know About Biological E's New COVID-19 Vaccine?
- healthIndia-US Healthcare Collaboration In Spotlight As India Approves Two More Covid-19 Vaccines
- healthPanel Recommends EUA For Covid-19 Vaccines Covovax, Corbevax And Anti-Covid Pill Molnupiravir
- healthBiological E Hopes To Roll Out COVID-19 Vaccine Corbevax By November-End
- disorders cureWhat Is ‘Centaurus,’ New Fast-Spreading Covid Variant: Everything You Need To Know
- health75 Years Of Independence, 75 Days Of Free COVID Booster Shots; For Everyone Aged 18-59 From 15 July
- wellnessWhat Are The Health Risks Of Getting COVID The Second Or Third Time? 7 Important Points